|
Á¸½¼¾ØµåÁ¸½¼ |
Sr. Medical Science Liaison (MSL) - IBD
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¼ö½Ãä¿ë |
3³â¡è |
ä¿ë½Ã |
11.28 |
|
|
Á¸½¼¾ØµåÁ¸½¼ |
[Çѱ¹¾á¼¾] 2023 »ó¹Ý±â ±Û·Î¹ú ÀÓ»ó °æ·Â»ç¿ø ´ë±Ô¸ð °øä
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.30 |
|
|
Agilent Korea |
[Çѱ¹¾ÖÁú·±Æ®] Sales (¿µ¾÷)
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.24 |
|
|
(ÁÖ)¸ðƼ¹ÙÄÚ¸®¾Æ |
±¹³»¿µ¾÷ °æ·Â»ç¿ø(°úÀå±Þ) ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
11³â¡è |
ä¿ë½Ã |
01.22 |
|
|
Äھƿ¥ |
RA ½Å±Ô ¸ðÁýÇÕ´Ï´Ù.
¼¿ï ¿µµîÆ÷±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.13 |
|
|
(ÁÖ)¸ðƼ¹ÙÄÚ¸®¾Æ |
¼¼ÀÏÁî&¸¶ÄÉÆÃÆÀ °æ·ÂÁ÷ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
11.13 |
|
|
Á¸½¼¾ØµåÁ¸½¼ |
[Á¸½¼¾ØµåÁ¸½¼ ¸ÞµðÄ®] Clinical Research Specialist
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
03.10 |
|
|
(ÁÖ)Æ÷¹ÙÀÌ¿ÀÄÚ¸®¾Æ |
[(ÁÖ)Æ÷¹ÙÀÌ¿ÀÄÚ¸®¾Æ] ¼¿ï º»»ç ÀǾàÇ° Ç°Áú°Ë»ç¼¾ÅÍ ¹× ±â
¼¿ï ±Ýõ±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.16 |
|
|
µå¸²ÆÑ ÁÖ½Äȸ»ç |
ÀÇ·á±â±â (2µî±Þ, Àü±âÀüÀÚ) Ç°ÁúÃ¥ÀÓÀÚ, ±ÔÁ¦Àü¹®°¡
¼¿ï Á¾·Î±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.03 |
|
|
½Å¶óÁ¨(ÁÖ) |
Clinical DeliveryÆÀ¿ø(CDA) ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
12.11 |
|
|
IQVIA¢â |
Manager, Global Site Activation (Regulatory and Start-up
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
08.11 |
|
|
Ƽ¾Ë¿¡½º³×Æ®¿÷½º |
¿µ¾÷¸¶ÄÏÆÃ
¼¿ï ÀüÁö¿ª, °æ±â ¼º³²½Ã ¼öÁ¤±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
½ÅÀÔ |
ä¿ë½Ã |
01.16 |
|
|
ÁöÀÌÇコÄɾîÄÚ¸®¾Æ |
Commercial Operation Specialist(»ç¿ø~´ë¸®±Þ)
¼¿ï Áß±¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
1³â¡è |
ä¿ë½Ã |
01.09 |
|
|
ÁöÀÌÇコÄɾîÄÚ¸®¾Æ |
Commercial Operation Leader (°úÀå~Â÷Àå±Þ)
¼¿ï Áß±¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
5³â¡è |
ä¿ë½Ã |
01.09 |
|
|
(ÁÖ)¾ÆÀνº¸Þµå |
[ÀÇ·á±â±â ±â¼ú¿µ¾÷ ½ÅÀÔ/°æ·Â] ¸¹Àº Áö¿ø ºÎŹµå¸³´Ï´Ù.
¼¿ï ±Ýõ±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.06 |
|